Timothy Leichliter, MD
Neurology · Pittsburgh, PANPI 1649568379
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $68,260 of the $99,265 with a category attached, or 68.8%. Neurocrine Biosciences, Inc. accounts for 67.1% of it on its own, with 18 other manufacturers making up the rest. Among neurology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $545.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$67K
- Teva Pharmaceuticals USA, Inc.$29K
- UCB, Inc.$2K
- MDD US Operations, LLC$525
- AbbVie$474
- Boston Scientific$374
- plus $677 from 13 others
Across 15 payments — averaging $1217.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$18K
What the payments were for
- Consulting fees$23,97524%
- Speaking & faculty fees$68,26069%
- Travel & lodging$2,3962%
- Food & beverage$4,6345%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 62 | $66,581 |
| Teva Pharmaceuticals USA, Inc. | 27 | $29,135 |
| UCB, Inc. | 2 | $1,500 |
| MDD US Operations, LLC | 23 | $525 |
| AbbVie | 28 | $474 |
| Boston Scientific | 4 | $374 |
| Lundbeck LLC | 9 | $148 |
| Amneal Pharmaceuticals LLC | 7 | $139 |
| Acadia Pharmaceuticals Inc | 3 | $79 |
| Adamas Pharmaceuticals, Inc. | 4 | $58 |
| Xeris Pharmaceuticals, Inc. | 2 | $49 |
| Vertical Pharmaceuticals, LLC | 3 | $42 |
| Revance Therapeutics, Inc. | 1 | $29 |
| Merz North America, Inc. | 1 | $29 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Mirum Pharmaceuticals, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Medtronic | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$65,163
- Austedo XR$28,899
- Neupro$1,500
- GENERAL DBS$366
How this compares
$99,265 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 195 | $1,023,335 |
| AustedoDeutetrabenazine | 128 | $1,001,444 |
| IngrezzaValbenazine Tosylate | 93 | $688,298 |
| GocovriAmantadine Hcl | 111 | $396,044 |
| RytaryCarbidopa/Levodopa | 292 | $340,612 |
| NeuproRotigotine | 210 | $231,626 |
| Austedo XrDeutetrabenazine | 28 | $189,475 |
| InbrijaLevodopa | 23 | $102,683 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 2,204 | $91,417 |
| NourianzIstradefylline | 30 | $69,801 |
| Rivastigmine | 322 | $51,387 |
| Rasagiline Mesylate | 233 | $39,728 |
| OngentysOpicapone | 43 | $35,480 |
| NuedextaDextromethorphan Hbr/Quinidine | 25 | $35,466 |
| AmantadineAmantadine Hcl | 740 | $32,393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $29,135 | $1,190,919156 claims |
| Acadia Pharmaceuticals IncNuplazid | $79 | $1,023,335195 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $66,581 | $723,778136 claims |
| MDD US Operations, LLCGocovri | $525 | $396,044111 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $139 | $359,168318 claims |
| UCB, Inc.Neupro | $1,500 | $231,626210 claims |
| Kyowa Kirin, Inc.Nourianz | $21 | $69,80130 claims |
| AbbVieBotox, Linzess | $474 | $36,81640 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $29 | $35,46625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Pittsburgh
- Anoopum GuptaPittsburgh$592K
- Thomas ScottPittsburgh$476K
- James ValerianoPittsburgh$416K
- Amber van LaarPittsburgh$413K
- Andrea SynowiecPittsburgh$386K
- Dolores Dominguez SantamariaPittsburgh$265K
- Heather MouryPittsburgh$186K
- Troy DesaiPittsburgh$174K
- Richard KasdanPittsburgh$172K
- David LobasPittsburgh$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.